Nebenwirkungen · Wegovy
Wegovy 1.5 mg tablets Wegovy 4 mg tablets Wegovy 9 mg tablets Wegovy 25 mg tablets · Abschnitt 4.8 · PDF-Seite 46
HOS-147356 · Präparat HOS-099634
Table 1 lists adverse reactions identified in clinical trials in adults and post-marketing reports. The frequencies are based, unless otherwise specified, on a pool of the subcutaneous semaglutide phase 3a trials (STEP 1-4), where 2650 adult patients were exposed to Wegovy. The duration of the trials was 68 weeks. The adverse reactions in OASIS 4 (204 adults with obesity or overweight with at least one weight-related comorbidity were exposed to oral semaglutide for 64 weeks) had similar frequencies to the subcutaneous phase 3a trials, except for dyspepsia which had a higher frequency category. Events not relevant for oral administration are omitted in the following overview.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T13:06:00Z · SHA-256 d18d21c1225b1515e1fb09608f43194fc51f46bec34dce897074f105b8785b7d · Passage 055c4c2a7967e93d4760b07a5ea0e86e9b434ecaab439ba887552f50ff1f7a3a · Zeichen 447–1130 im Abschnitt